2
|
Sahu B, Leon LM, Zhang W, Puranik N, Periasamy R, Khanna H, Volkert M. Oxidative Stress Resistance 1 Gene Therapy Retards Neurodegeneration in the rd1 Mutant Mouse Model of Retinopathy. Invest Ophthalmol Vis Sci 2021; 62:8. [PMID: 34505865 PMCID: PMC8434758 DOI: 10.1167/iovs.62.12.8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 05/19/2021] [Indexed: 12/17/2022] Open
Abstract
Purpose Oxidative stress is a major factor underlying many neurodegenerative diseases. However, antioxidant therapy has had mixed results, possibly because of its indiscriminate activity. The purpose of our study was to determine if the human OXR1 (hOXR1) antioxidant regulatory gene could protect neurons from oxidative stress and delay photoreceptor cell death. Methods The cone-like 661W cell line was transfected to stably express the hOXR1 gene. Oxidative stress was induced by the addition of hydrogen peroxide (H2O2). Intracellular levels of reactive oxygen species (ROS), caspase cleavage, and cellular resistance to oxidative stress were determined and compared between the control and hOXR1 cells. For in vivo analysis, AAV8-hOXR1 was injected subretinally into the rd1 mouse model of retinal degeneration. Functional and structural integrity of the photoreceptors were assessed using electroretinography (ERG), histology, and immunofluorescence analysis. Results Expression of hOXR1 increased cellular resistance and reduced ROS levels and caspase cleavage in the 661W cell line after H2O2-induced oxidative stress. Subretinal injection of AAV8-hOXR1 in the rd1 mice improved their photoreceptor light response, expression and localization of photoreceptor-specific proteins, and delayed retinal degeneration. Conclusions Our results suggest that OXR1 is a potential therapy candidate for retinal degeneration. Because OXR1 targets oxidative stress, a common feature of many retinal degenerative diseases, it should be of therapeutic value to multiple retinal degenerative diseases.
Collapse
Affiliation(s)
- Bhubanananda Sahu
- Department of Ophthalmology and Visual Science, University of Massachusetts Medical School, Worcester, Massachusetts, United States
- Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, United States
| | - Laura Moreno Leon
- Department of Ophthalmology and Visual Science, University of Massachusetts Medical School, Worcester, Massachusetts, United States
- Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, United States
| | - Wei Zhang
- Department of Ophthalmology and Visual Science, University of Massachusetts Medical School, Worcester, Massachusetts, United States
- Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, United States
| | - Nikita Puranik
- Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, United States
| | - Ramesh Periasamy
- Department of Ophthalmology and Visual Science, University of Massachusetts Medical School, Worcester, Massachusetts, United States
- Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, United States
| | - Hemant Khanna
- Department of Ophthalmology and Visual Science, University of Massachusetts Medical School, Worcester, Massachusetts, United States
- Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, United States
- NeuroNexus Institute, University of Massachusetts Medical School, Worcester, Massachusetts, United States
| | - Michael Volkert
- NeuroNexus Institute, University of Massachusetts Medical School, Worcester, Massachusetts, United States
- Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, United States
| |
Collapse
|
3
|
Leon LM, Gautier M, Allan R, Ilié M, Nottet N, Pons N, Paquet A, Lebrigand K, Truchi M, Fassy J, Magnone V, Kinnebrew G, Radovich M, Cheok MHC, Barbry P, Vassaux G, Marquette CH, Ponzio G, Ivan M, Pottier N, Hofman P, Mari B, Rezzonico R. Correction: The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene 2021; 40:2621. [PMID: 33686243 DOI: 10.1038/s41388-021-01670-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Lung cancer is the leading cause of cancer death worldwide, with poor prognosis and a high rate of recurrence despite early surgical removal. Hypoxic regions within tumors represent sources of aggressiveness and resistance to therapy. Although long non-coding RNAs (lncRNAs) are increasingly recognized as major gene expression regulators, their regulation and function following hypoxic stress are still largely unexplored. Combining profiling studies on early-stage lung adenocarcinoma (LUAD) biopsies and on A549 LUAD cell lines cultured in normoxic or hypoxic conditions, we identified a subset of lncRNAs that are both correlated with the hypoxic status of tumors and regulated by hypoxia in vitro. We focused on a new transcript, Nuclear LUCAT1 (NLUCAT1), which is strongly upregulated by hypoxia in vitro and correlated with hypoxic markers and poor prognosis in LUADs. Full molecular characterization showed that NLUCAT1 is a large nuclear transcript composed of six exons and mainly regulated by NF-κB and NRF2 transcription factors. CRISPR-Cas9-mediated invalidation of NLUCAT1 revealed a decrease in proliferative and invasive properties, an increase in oxidative stress and a higher sensitivity to cisplatin-induced apoptosis. Transcriptome analysis of NLUCAT1-deficient cells showed repressed genes within the antioxidant and/or cisplatin-response networks. We demonstrated that the concomitant knockdown of four of these genes products, GPX2, GLRX, ALDH3A1, and PDK4, significantly increased ROS-dependent caspase activation, thus partially mimicking the consequences of NLUCAT1 inactivation in LUAD cells. Overall, we demonstrate that NLUCAT1 contributes to an aggressive phenotype in early-stage hypoxic tumors, suggesting it may represent a new potential therapeutic target in LUADs.
Collapse
Affiliation(s)
- Laura Moreno Leon
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Marine Gautier
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Richard Allan
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Marius Ilié
- FHU-OncoAge, Nice, France.,Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.,Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Nice, France
| | - Nicolas Nottet
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Nicolas Pons
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Agnes Paquet
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Kévin Lebrigand
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Marin Truchi
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Julien Fassy
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Virginie Magnone
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Garrett Kinnebrew
- Department of Surgery, Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Milan Radovich
- Department of Surgery, Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Meyling Hua-Chen Cheok
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistence, Lille, Cedex, France
| | - Pascal Barbry
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Georges Vassaux
- FHU-OncoAge, Nice, France.,Université Côte d'Azur, INSERM, CNRS UMR7275, IPMC, Valbonne, France
| | - Charles-Hugo Marquette
- FHU-OncoAge, Nice, France.,Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.,Department of Pneumology, CHU-Nice, Nice, France
| | - Gilles Ponzio
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France.,FHU-OncoAge, Nice, France
| | - Mircea Ivan
- Department of Medicine and Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Nicolas Pottier
- EA4483, Faculté de Médecine de Lille, Pole Recherche, Lille, France
| | - Paul Hofman
- FHU-OncoAge, Nice, France.,Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.,Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Nice, France
| | - Bernard Mari
- Université Côte d'Azur, CNRS UMR7275, IPMC, Valbonne, France. .,FHU-OncoAge, Nice, France.
| | - Roger Rezzonico
- FHU-OncoAge, Nice, France. .,Université Côte d'Azur, INSERM, CNRS UMR7275, IPMC, Valbonne, France.
| |
Collapse
|